A B S T R A C T Parameters of mineral and bone metabolism were studied in 17 patients treated chronically with supraphysiologic doses of glucocorticoids. When compared to 15 matched normal subjects, the patient group exhibited similar serum 25-hydroxyvitamin D (25-OHD) levels, decreased intestinal 47Ca absorption, increased serum immunoreactive parathyroid hormone, and decreased forearm bone mass. Iliac crest bone biopsies revealed a decreased bone formation rate and increased osteoclast number. Treatment with 25-OHD (mean dose 40.3 ,ug/d) and calcium (500 mg/d) in nine patients produced a 46% increase in 47Ca absorption (P < 0.001) and a 54% decrease in serum immunoreactive parathyroid hormone (P <0.001) by 3 mo. In addition, by 12 mo the treatment group exhibited (a) a 13.2+5.1% increase in metaphyseal (P < 0.001) and a 2.1+0.4% increase in diaphyseal (P < 0.05) forearm bone mass, and (b) significant decreases in cortical and endosteal osteoclast number. Biochemical and bone mass changes persisted through 18 mo. No significant changes in any parameter occurred in eight control patients administered calcium 100 mgld. It is concluded that treatment with 25-OHD and calcium can significantly improve parameters of mineral and bone metabolism in patients with glucocorticoid-induced osteopenia.
INTRODUCTION
Chronic maintenance of supraphysiologic levels of glucocorticoids, whether of enodgenous or exogenous Dr. Hahn is the recipient of National Institutes of Health Research Career Development Award NS70540. Received for publication 11 October 1978 and in revised form 19 April 1979. origin, is commonly associated with the development of severe osteopenia in man (1) (2) (3) (4) (5) (6) . Histologic studies of bone in patients with steroid-induced osteopenia have demonstrated both decreased formation rates and increased numbers of osteoclasts and resorption sites (7, 8) . The decrease in formation rate has been attributed to an inhibitory effect on osteoblast function. Moderate doses of glucocorticoids decrease both the synthesis of collagen by preexisting osteoblasts and the recruitment of progenitor cells to functioning osteoblasts (7) (8) (9) (10) . This reduced function apparently represents a direct cellular effect since the addition of cortisone to osteoblasts in culture markedly reduces protein synthesis (10) .
Steroid-induced increases in bone resorption rates have been variously attributed to either direct stimulation of osteoclast activity or increased parathyroid hormone (PTH)1 secretion. However, glucocorticoids do not directly stimulate bone resorption in vitro (11) and parathyroidectomy abolishes the osteoclastic response in animals (12) . Moreover, it has been recently demonstrated that chronic glucocorticoid administration in man is associated with elevated serum immunoreactive PTH (iPTH) concentrations (13) (14) (15) which can be suppressed by calcium infusion (14) . Thus it appears likely that the increased bone resorptive activity is due to an increase in PTH secretion presumably secondary, at least in part, to inhibition of intestinal calcium absorption (16) (17) (18) (19) .
The basis for the inhibitory effect of glucocorticoids on intestinal calcium transport remains controversial. Several authors have suggested that glucocorticoids 1Abbreviations used in this paper: iPTH, immunoreactive may reduce serum 25-hydroxyvitamin D (25-OHD) concentration either by impairing the hepatic conversion of vitamin D to 25-OHD or by altering subsequent 25-OHD metabolism (19) (20) (21) . In contrast, others have reported normal conversion of [3H]vitamin D3 to its active metabolites in cortisone-treated rats (17, 22) and normal serum 25-OHD concentrations, measured by competitive-protein binding assay, in steroid-treated patients (23, 24) . This question remains unresolved; however, it has been reported that administration of vitamin D in doses of 50,000-100,000 U/wk for 12 wk or 0. 4 ,ug/d of 1,25-(OH)2D3 for 7 d significantly increases intestinal calcium absorption in steroidtreated patients (18, 19) . This being the case, we hypothesized that restoring intestinal calcium absorption to normal levels in such patients by administering 25 -OHD and calcium supplements would suppress PTHinduced increases in resorption rates, thereby favorably affecting bone mineral status. The results of our studies indicate that such a regimen does indeed produce a substantial improvement in mineral metabolism parameters.
METHODS
17 patients with glucocorticoid-induced osteopenia were chosen for study. Criteria for the diagnosis included (a) treatment with supraphysiologic doses of glucocorticoids (>7.5 mg prednisone-equivalents/d) for a least 1.5 yr, (b) osteopenia detectable by routine radiographic techniques, and (c) a characteristic disproportionately greater loss of metaphyseal relative to diaphyseal bone mass in the radius as determined by our previously described photon absorption technique (6) .
Criteria for inclusion in the study included (a) relatively stable glucocorticoid dose (<25% change in dose over the preceding 6 mo), (b) a creatinine clearance of >80 and calcium intake and hours of sunlight exposure as previously described (25) . Physical functional status was determined by the Steinbrocker criteria (26) .
Bone mass was determined by our previously described photon absorption technique (6) in the radius of the lesserused arm at two locations: a metaphyseal site 2 cm proximal to the distal end of the ulna and a diaphyseal site one-third the distance from the distal to proximal end of the radius. At least four scans were performed at each site. The proximal site is composed primarily of cortical bone whereas the distal site contains a relatively greater proportion of trabecular bone (27) . Values were calculated as grams per square centimeter and expressed as a percent of mean age-sex normal values based on our previously established norms (6) . The accuracy of this technique is -4% and the precision 2-3% (8 An unstained 10-,m section was then examined by fluorescent microscopy to measure the tetracycline-based parameters in those patients who had been administered the tetracycline labels. The following variables were quantitated as previously described (34): (a) cellular rate of mineralization, the mean distance (micrometers) between all double-fluorescent markers within trabecular bone divided by the number of days between administration of the labels (representing the rate at which mineralization occurs at the average bone-forming surface), and (b) linear extent of bone mineralization, the absolute extent (micrometers) of bone forming surface (i.e., surface exhibiting a double tetracycline label) per square millimeter trabecular space.
After the completion of base-line studies, patients in the treatment group were begun on a regimen of25-OHD ,ug/d) plus calcium 500 mg (as calcium carbonate) daily, whereas controls were placed on a minimal calcium supplement (100 mg/d). The dose of 25-OHD was subsequently adjusted at biweekly intervals to maintain urinary calcium excretion below 300 mg/24 h.
The significance of differences between group means was determined by Dunnett's multiple variable t test method (35) , correlation coefficients were calculated by Pearson's formula, and reduced major regression axes were determined by the method of Kermack and Haldane (36) . All results are reported as mean±standard error of the mean.
RESULTS
Basal biochemical parameters. Clinical characteristics and dietary history data for the patient groups and normal subjects are summarized in Table I . There were no significant differences in age and sex distribution or dietary intake between patients and normal subjects. Moreover, treatment and control patient groups were quite similar with regard to mean daily glucocorticoid dose, duration oftherapy, and functional class.
Mean serum concentrations of total and ionized calcium, phosphorus, alkaline phosphatase, and 25-OHD in the steroid-treated patients did not differ significantly from those in normal subjects (Table II) . However, mean serum iPTH concentration in the steroid-treated subjects was approximately twice the mean normal value, and serum iPTH exhibited an inverse correlation with serum ionized calcium concentration (r = -0.40, P < 0.05). 24-h urinary calcium excretion expressed both as mg/g creatinine per 24 h and mg/kg body wt per 24 h was not significantly different between the two groups. However, intestinal 47Ca absorption (percent of 100 mg dose) was significantly reduced in steroid-treated subjects, averaging 59% of the normal value. No significant correlation was observed between serum 25-OHD concentration and percent 47Ca absorption (r = 0.07, P > 0.50). However, there was a statistically significant inverse correlation of serum iPTH concentration with intestinal 47Ca absorption (r = -0.52, P < 0.02).
As shown in Table III , bone mass measured by the photon absorption method was reduced by 7.7%+3.2% (P < 0.05) in the diaphyseal region of the radius and by 33 .0%+3.1% (P < 0.001) in the metaphyseal region in glucocorticoid-treated patients relative to normal (Fig. 1) . Concurrently, mean serum total calcium concentration showed a slight but significant increase (Fig. 1) at 0, 3, 6, 9, and 12 mo, respectively. Neither serum calcium concentration nor 24-h urinary calcium excretion changed significantly in control patients.
Intestinal 47Ca absorption in 25-OHD-treated patients was increased by a mean of 45.5% (P < 0.001) above base-line values at 3 mo, the earliest time point examined (Fig. 2) , and was maintained at similar levels during the remainder of the initial 12 mo of treatment. Mean percent intestinal 47Ca absorption in treated patients at the end of 12 mo was 57.1+2.3%, slightly but not significantly below that of the mean value for normal subjects (63.7+4.6%, P > 0.10); mean percent 47Ca absorption in untreated patients remained significantly reduced at 43.0+4.6% (P < 0.001 compared to normals).
Concurrent with the increase in intestinal 47Ca absorption, serum iPTH concentration fell significantly after 25-OHD treatment, reaching a mean value not significantly different from normal by 3 mo and remaining essentially unchanged during the remainder of the study (Fig. 2) . Values for serum iPTH concentration during the period of 25-OHD treatment showed a strong inverse correlation with 47Ca absorption (r = -0.71, P < 0.001). In control subjects the serum iPTH concentration remained elevated.
As shown in Fig. 3 However the difference in mean changes observed at 12 mo in the 25-OHD-treated and control groups was highly significant (P < 0.001). Changes in metaphyseal mass were more striking. By 5 mo of treatment a significant increase in metaphyseal mass in the 25-OHD-treated subjects was observed, with the 10.3+5.7% increase being statistically sig-60 (yg/d) nificant at P < 0.01 by paired data analysis. No further 096 (pg/kg/d) statistically significant increase in metaphyseal mass was observed after this time. The 12-mo mean increase over base line averaged 13.2±5.1%. Again, no n with serum significant change in metaphyseal bone mass was atients. The observed in control subjects although there appeared to instraltion be a slight downward trend with time; 12 -mo values in of the nine control subjects declined -2.8+1.2% from base line.
The difference in percent change in metaphyseal mass at 12 mo in treated and control subjects was again P < 0.001). highly significant (P < 0.001). Although in the 25 Correlation of serum 25 The results of more prolonged follow-up of25-OHDtreated and control subjects are presented in Table IV . After a mean period of 18 mo on treatment, the 25-OHD-treated patients maintained the improved intestinal 47Ca absorption, serum iPTH, and bone mass status observed after 12 mo oftreatment. There were no statistically significant differences between 12-and 18-mo values for either the treated or control groups.
Bone histology. When compared to the normal subjects, the glucocorticoid-treated patients were osteopenic and had an excess of osteoid (Table V) . The mean trabecular bone volume was 61.5% of normal and the average relative osteoid volume in patient biopsies was more than twice that of controls. However, since the percent total osteoid surface in the steroid-treated patients was almost three times that observed in con- Values represent mean+SEM. Numbers of subjects are indicated in parentheses. * Significantly different from normals at P < 0.05.
I Significantly different from normals at P < 0.02. § Significantly different from normals at P < 0.005. trol biopsies, the osteoid seams tended to be thinner than normal. Additionally, there were abundant skeletal cells in the bones of the glucocorticoid-treated patients. The percent osteoblastic-osteoid surface was increased and the number ofosteoclasts within trabecular bone averaged three times normal, although this latter difference was not statistically significant. The only significant histologic difference between the control and 25-OHD treatment patient groups observed on the initial biopsies related to osteoclasts on the cortical-endosteal surface (Table VI) . The number of these cells was significantly less (P < 0.05) in the control group than in the 25-OHD treatment group. On the other hand, after therapy the number of osteoclasts per square millimeter of cortical endosteal bone surface was greater in the control than in the 25-OHDtreated patients (P < 0.05). Furthermore, posttreatment biopsies in the 25-OHD group contained fewer osteoclasts per square millimeter of cortical bone than did those of control patients (P < 0.05). No other significant differences existed between the posttreatment biopsies of 25-OHD-treated and control subjects.
As compared to published normal values (37) , the cellular rate of mineralization was suppressed in four pretreatment biopsies of patients in the 25-OHD treatment group and in one of four control subjects in whom this parameter was examined (Table VII) . Indeed, three of the four initial biopsies of the 25-OHD group and one initial biopsy of the control group contained no double-fluorescent tetracycline labels. Three of the four second biopsies in the 25-OHD-treated group exhibited normal cellular mineralization rates. On the subjects at the indicated times.
other hand, the second biopsy taken from the control patient whose initial biopsy contained no fluorescent labels again exhibited no evidence of bone mineralization. However, these differences between groups were not statistically significant. There were also no significant changes in either group in the linear extent of bone mineralization, which reflects the extent of bone surface involved in active bone formation. However, although the mean linear extent of bone mineralization decreased in the control patients, after 12 mo there was an increase in the mean linear extent ofbone mineralization in 25-OHD-treated patients.
DISCUSSION
In the present study decreased intestinal calcium absorption, increased serum iPTH concentrations, (38) . In addition, the slight decrease in mean urinary calcium excretion in our patients, relative to normal subjects, may in part reflect the renal tubular calcium-retaining effects of increased circulating PTH concentrations (39) .
Pretreatment serum 25-OHD levels in our patients were normal and showed no significant correlation with intestinal 47Ca absorption. These data are in concert with previous reports from this laboratory as well as others (23, 24) . However, they are somewhat in contrast to the observations of Klein In response to supplementation with 25-OHD at a mean dose of 40 ,ug/d, intestinal calcium absorption rose to approximately normal levels and serum iPTH was reduced. Stimulation of calcium absorption may have been the result of both the effects of an increased circulating 25-OHD concentration and the marked increase in local 25-OHD concentration at the intestinal mucosal cell as a result of oral 25-OHD administration. At the point at which 47Ca absorption was normalized, serum 25-OHD concentrations were in the range of 100 ng/ml, approximately five times normal levels. This disparity suggests a relative resistance to the calcium absorption-stimulating effects of 25-OHD.
It could be proposed that this apparent resistance was the result of glucocorticoid-induced alterations in the conversion of 25-OHD to 1,25-(OH)2D, the apparent final and most biologically potent vitamin D metabolite (43) . This viewpoint is supported by the observations of (a) Carre et al. (21) who have suggested that glucocorticoids may accelerate the metabolism of 1,25-(OH)2D3 to an inactive product, and (b) Klein et al. (19) who have reported that 1,25-(OH)2D3 in near-physiologic doses can restore intestinal calcium absorption to approximately normal levels in glucocorticoid-treated individuals. On the other hand, it has been reported that conversion of vitamin D3 to 1,25-(OH)2D3 and localization of 1,25-(OH)2D3 in intestinal mucosal cell nuclei proceeds normally in cortisone-treated rats (22) . However, because serum 1,25-(OH)2D levels were not measured in our patients, our present data do not allow us to choose between hypotheses regarding the mechanism of resistance to 25-OHD.
At the bone level, treatment with 25-OHD and calcium was accompanied by a significant decrease in osteoclast number. This decrease can apparently be attributed to suppression of PTH secretion, since it has been demonstrated that the osteoclastic response to glucocorticoids is mediated through increased PTH activity, whereas the suppression of bone formation is apparently the result of a direct effect on osteoblast function (10) . It is of interest that double fluorescent labels were present in the post-25-OHD treatment biopsies of three individuals whose initial biopsies showed no evidence of bone formation. However, the number of patients receiving time-spaced tetracycline labels is too few to draw definite conclusions regarding effects on bone accretion rates. Thus, the histomorphometric changes suggest that the net increase in bone mass demonstrated by photon absorption densitometry resulted at least in part from decreased osteoclastic resorptive activity, with the possibility existing that the bone formation rate may have been increased concurrently. Since bone mass measured by photon absorption was not increasing detectably at 12 mo in the 25-OHD-treated group, the bone histomorphometric parameters at that point may reflect a new steady state of formation and resorption under the influence of 25-OHD administration.
It is not surprising that the most marked increment in bone mass was observed at the metaphyseal site, since this region contains a larger proportion of more metabolically active bone and exhibits the greatest degree of change in states of increased parathyroid activity (6, 9, 27 Secondly, since bone formation and resorption rates frequently change in parallel fashion (45) , a reduction in bone resorption rate might ultimately be accompanied by a concomitant decline in bone formation. If this were to occur, a later decrease in bone mass might follow with formation and resorption restored to their previous equilibrium, albeit at a lower level of bone turnover. However, no evidence ot a secondary decrement in bone mass was observed in our patients.
Finally, since the resistance of bone to stress fracture correlates positively with bone mass as determined by photon absorption densitometry (46) , the observed increase in bone mass might ultimately lead to a reduced propensity to bone fractures in glucocorticoidtreated patients receiving 25-OHD chronically. However, the clinical efficacy of this mode of treatment remains to be determined.
